MilliporeSigma, Canada and US life science businesses of Merck KGaA, Germany, a leading science and technology company, announced that its life science business industry is investing over 286 million dollars in the biosafety testing capacity at the company’s site in Rockville, USA.
This investment will significantly increase the ability of the company to conduct biosafety testing and analytical development services. Biosafety testing and analytical development have been critical and fundamental requirements for the development and commercialization processes of the drug to ensure the safety of medicines.
MilliporeSigma has been harnessing its broad portfolio of modern technologies and will enable services to ensure the safety of medicines across the world. These investments in Maryland site and several other sites across their global network will help the company to meet growing demand for the robust test studies that biologics producers depend upon to comply with strict regulatory guidelines, said Belen Garijo, CEO of Merck KGaA, Darmstadt, Germany.
Belen Garijo added that this is a prime example of their focus on sustainable growth in areas with strong dynamics. This is the biggest investment in contract testing in the company, and their Rockville plant has a long track record of testing for both novel and traditional therapies.
Writing is a medium to express feelings and convey facts. A creative mind never rests in peace and this amazing platform gives me the freedom to write about what I like most.
I’ve been a writer/blogger for the last twelve years and have covered technology-related topics. However, I also have considerable years of experience in writing for various domains – Technology, Beauty, Fashion, Pharmaceutical, human psychology etc. Technology is my forte.
I’ve handled many interesting projects. Writing is my passion. As an author, I’ve learned a lot in my long journey of penning down my thoughts!
